Business Details
Advanced FISH Technology for Cancer Diagnostics
Ikonisys stands as a global leader in Fluorescence In Situ Hybridization (FISH) technology, dedicated to advancing cancer diagnostics through innovation and precision. With over two decades of research and development, the company has pioneered automated microscopy solutions that empower laboratories worldwide with unparalleled accuracy in detecting genetic abnormalities. Our proprietary technology integrates hardware, software, and reagents to deliver high-speed, reliable diagnostic tools that enhance workflow efficiency and support personalized medicine. By focusing on automation and digital imaging, we reduce human error while increasing throughput, enabling pathologists and technicians to achieve superior diagnostic outcomes.Our commitment to regulatory compliance, including FDA clearance and ISO13485 certification, underscores our dedication to quality and reliability. Through strategic partnerships and a customer-centric approach, we provide tailored solutions that address the evolving needs of oncology diagnostics. With a presence in the USA, Europe, and Asia, Ikonisys continues to drive breakthroughs in genetic analysis, contributing to improved patient care and outcomes in the fight against cancer.
Services
FISH Microscopy
Cancer Diagnostics
Automated Screening
Genetic Analysis
Pathology Solutions
Highlights and features
- 20 years of R&D in automated FISH technology
- FDA-cleared and CE-marked diagnostic applications
- Proprietary hardware/software integration for unmatched accuracy
- Global regulatory compliance with ISO13485 standards
- Dedicated support for laboratory workflow optimization
Associations and certifications
- FDA
- CE Mark
- ISO13485
Services
FISH Microscopy
Our automated fluorescence microscopy systems combine high-resolution imaging with AI-powered analysis to detect chromosomal abnormalities in cancer cells. The technology enables pathologists to identify genetic markers with 99% accuracy, supporting precise diagnosis and treatment planning for hematological and solid tumor cancers through standardized, reproducible results.
Cancer Diagnostics
We provide comprehensive diagnostic solutions for detecting genetic mutations associated with leukemia, breast cancer, bladder cancer, and other malignancies. Our FDA-cleared applications analyze tissue samples and circulating tumor cells to identify translocations, amplifications, and deletions that guide targeted therapies and monitor treatment response with clinical-grade precision.
Automated Screening
Our AI-driven platforms automate the detection and enumeration of rare cancer cells in biological samples, reducing manual analysis time by 70% while maintaining diagnostic accuracy. The system processes up to 160 slides per day with minimal technician intervention, optimizing laboratory workflow efficiency for high-volume diagnostic operations.
Questions
What is Ikonisys' core technology?
We specialize in automated FISH (Fluorescence In Situ Hybridization) technology for cancer diagnostics, combining proprietary microscopy hardware, AI-driven software, and specialized reagents.
How does your FISH technology improve cancer diagnosis?
Our platform enables high-speed, automated detection of chromosomal abnormalities with 99% accuracy, supporting early diagnosis and treatment monitoring for various cancers.
What regulatory certifications do you hold?
Our systems are FDA-cleared in the USA, CE-marked in Europe, and manufactured under ISO13485-certified quality management systems.
Do you offer global support?
Yes, we provide technical and service support across North America, Europe, and Asia through our regional offices and authorized distributors.
What clinical applications does your system support?
Our platform supports hematological malignancies, solid tumor analysis, HER2 testing, and circulating tumor cell detection with customizable assay configurations.